Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …

The approach of peptide-based anticancer vaccination has proven the ability to induce
cancer-specific immune responses in multiple studies for various cancer entities. However …

Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease …

Existing strategies to enhance peptide immunogenicity for cancer vaccination generally
require direct peptide alteration, which, beyond practical issues, may impact peptide …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …

Conventional vaccine strategies have been highly efficacious for several decades in
reducing mortality and morbidity due to infectious diseases. The bane of conventional …

The presentation of exogenous antigens on MHC class I molecules, known as cross-
presentation, is essential for the initiation of CD8+ T cell responses. In vivo, cross …

Peptide-based cancer vaccines rely upon the strong activation of the adaptive immune
response to elicit its effector function. They have shown to be highly specific and safe, but …